Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and <scp>Meta‐Analysis</scp> of Prospective, Controlled Clinical Trials-Reference-Cited by-同舟云学术

Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials

Published:2022-10-11 Issue:6 Volume:112 Page:1303-1317
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Brown Lisa C.¹^ORCID,Stanton Joseph D.²,Bharthi Kanika³,Maruf Abdullah Al⁴⁵⁶,Müller Daniel J.⁷⁸⁹,Bousman Chad A.⁴¹⁰¹¹^ORCID

Affiliation:

1. Great Scott! Consulting New York New York USA

2. Tempus Labs Chicago Illinois USA

3. Department of Biological Sciences University of Calgary Calgary Alberta Canada

4. The Mathison Centre for Mental Health Research and Education, Hotchkiss Brain Institute, Cumming School of Medicine University of Calgary Calgary Alberta Canada

5. College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada

6. Children's Hospital Research Institute of Manitoba Winnipeg Manitoba Canada

7. Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health Toronto Ontario Canada

8. Department of Psychiatry University of Toronto Toronto Ontario Canada

9. Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health University Hospital of Würzburg Würzburg Germany

10. Departments of Medical Genetics, Psychiatry, Physiology and Pharmacology, and Community Health Sciences University of Calgary Calgary Alberta Canada

11. Alberta Children's Hospital Research Institute University of Calgary Calgary Alberta Canada

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2748

Reference38 articles.

1. The STAR*D project results: A comprehensive review of findings

2. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System

3. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later

4. Pharmacogenetics: From Bench to Byte— An Update of Guidelines

5. FDA.Table of pharmacogenomic biomarkers in drug labeling.https://www.fda.gov/drugs/science‐and‐research‐drugs/table‐pharmacogenomic‐biomarkers‐drug‐labeling. Accessed April 27 2022.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug metabolizing enzymes pharmacogenetic variation-informed antidepressant therapy approach for common mental disorders: A systematic review and meta-analysis;Journal of Affective Disorders;2024-12

2. Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review;Therapeutic Drug Monitoring;2024-09-11

3. Exploring Youth-Perceived Barriers and Attitudes Towards the Clinical Use of Pharmacogenetic Testing to Optimise Antidepressant Pharmacotherapy;2024-08-26

4. Biomarkers in the Diagnosis and Prediction of Medication Response in Depression and the Role of Nutraceuticals;International Journal of Molecular Sciences;2024-07-22

5. Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis;Frontiers in Psychiatry;2024-07-11